Blood pressure drug may halt liver damage in hep c patients
NCT ID NCT00265642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placebo. The main goal was to measure changes in liver scar tissue using biopsies and blood tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Angers, Service d'hépato-gastroentérologie
Angers, 49933 cedex 09, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Simple support strategies may help curb hepatitis c in appalachia
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users